Insider Selling: VanEck Biotech ETF (NASDAQ:BBH) Major Shareholder Sells $109,166.43 in Stock

VanEck Biotech ETF (NASDAQ:BBH) major shareholder Sardar Biglari sold 6,533 shares of the stock in a transaction on Wednesday, July 15th. The stock was sold at an average price of $16.71, for a total value of $109,166.43. Following the transaction, the insider owned 3,552,710 shares of the company’s stock, valued at $59,365,784.10. The trade was a 0.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Sardar Biglari also recently made the following trade(s):

• On Thursday, July 16th, Sardar Biglari sold 2,749 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.70, for a total value of $45,908.30.
• On Tuesday, July 14th, Sardar Biglari sold 1,211 shares of VanEck Biotech ETF stock. The shares were sold at an average price of $16.73, for a total transaction of $20,260.03.

VanEck Biotech ETF Price Performance

NASDAQ:BBH traded up $2.26 on Thursday, reaching $206.25. 3,431 shares of the company’s stock were exchanged, compared to its average volume of 6,008. VanEck Biotech ETF has a 52 week low of $154.75 and a 52 week high of $212.54. The stock has a fifty day simple moving average of $192.26 and a 200-day simple moving average of $191.76.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Empowered Funds LLC purchased a new stake in shares of VanEck Biotech ETF during the fourth quarter worth $38,000. Flagship Harbor Advisors LLC purchased a new position in shares of VanEck Biotech ETF in the fourth quarter valued at $47,000. Allworth Financial LP raised its stake in shares of VanEck Biotech ETF by 255.0% during the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after purchasing an additional 306 shares during the period. Fifth Third Bancorp bought a new stake in shares of VanEck Biotech ETF during the 1st quarter valued at $127,000. Finally, Huntington National Bank purchased a new stake in VanEck Biotech ETF during the 4th quarter worth about $132,000. 32.05% of the stock is currently owned by hedge funds and other institutional investors.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.